4547:TYO
Kissei Pharmaceutical Co Ltd
၃,၇၁၀.၀၀ JP¥
arrow_upward
+၀.၄၁%(+၁၅.၀၀) 1D
အောက် ၉, GMT+၉ ၁၅:၃၀:၀၀ · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
၃,၇၂၅ JP¥
High
၃,၇၄၅ JP¥
Low
၃,၇၀၅ JP¥
Mkt. cap
ဋေ ၁.၇၃ သ
Avg. vol.
၆.၉၃ သောင်း
Volume
၈.၆၉ သောင်း
Dividend
၃.၂၃%
Quarterly dividend
၃၀ JP¥
Ex-dividend date
၂၀၂၆ စက် ၂၉
P/E ratio
၁၁.၀၀
52-wk high
၅,၀၄၀ JP¥
52-wk low
၃,၅၀၀ JP¥
EPS
၃၃၇ JP¥
Shares outstanding
၄.၆၇ ကုဋေ
No. of employees
၂ ထောင်
Open
၃,၇၂၅ JP¥
High
၃,၇၄၅ JP¥
Low
၃,၇၀၅ JP¥
Mkt. cap
ဋေ ၁.၇၃ သ
Avg. vol.
၆.၉၃ သောင်း
Volume
၈.၆၉ သောင်း
Dividend
၃.၂၃%
Quarterly dividend
၃၀ JP¥
Ex-dividend date
၂၀၂၆ စက် ၂၉
P/E ratio
၁၁.၀၀
52-wk high
၅,၀၄၀ JP¥
52-wk low
၃,၅၀၀ JP¥
EPS
၃၃၇ JP¥
Shares outstanding
၄.၆၇ ကုဋေ
No. of employees
၂ ထောင်
News stories
From web sources and news partners
TradingView
·
ပြီးခဲ့သည့် ၄ နာရီ
Crypto's Next Big Opportunity? Nasdaq CEO Highlights Tokenization's Billion-Dollar Potential
Simply Wall Street
·
ပြီးခဲ့သည့် ၅ မိနစ်
How Declining Sales At Surgery Partners (SGRY) Has Changed Its Investment Story
24/7 Wall St.
·
ပြီးခဲ့သည့် ၄၀ မိနစ်
KLA Turned $1,000 Into $31,595 in a Decade, Crushing the S&P 500 by 8.7x
Yahoo Finance
·
ပြီးခဲ့သည့် ၅၁ မိနစ်
Pokémon Cards Just Crushed Bitcoin, Gold and the S&P 500 With 150% Returns
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees၁.၇၉ ထောင်
Founded၁၉၄၆ ဩ ၉
HeadquartersMatsumoto, Nagano, ဂျပန်
Sector-
Websitekissei.co.jp